Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Variable Features of Juvenile Polyposis Syndrome With Gastric Involvement Among Patients With a Large Genomic Deletion of BMPR1A.

Lieberman S, Beeri R, Walsh T, Schechter M, Keret D, Half E, Gulsuner S, Tomer A, Jacob H, Cohen S, Basel-Salmon L, Mansur M, Berger R, Katz LH, Golomb E, Peretz T, Levy Z, Kedar I, King MC, Levy-Lahad E, Goldberg Y.

Clin Transl Gastroenterol. 2019 Jul;10(7):e00054. doi: 10.14309/ctg.0000000000000054.

2.

Homozygosity for CHEK2 p.Gly167Arg leads to a unique cancer syndrome with multiple complex chromosomal translocations in peripheral blood karyotype.

Paperna T, Sharon-Shwartzman N, Kurolap A, Goldberg Y, Moustafa N, Carasso Y, Feinstien M, Mory A, Reznick-Levi G, Gonzaga-Jauregui C, Shuldiner AR, Basel-Salmon L, Ofran Y, Half EE, Baris Feldman H.

J Med Genet. 2019 Mar 11. pii: jmedgenet-2018-105824. doi: 10.1136/jmedgenet-2018-105824. [Epub ahead of print]

PMID:
30858171
3.

Screening to Detect Precursor Lesions of Pancreatic Adenocarcinoma in High-risk Individuals: A Single-center Experience.

Lachter J, Rosenberg C, Hananiya T, Khamaysi I, Klein A, Yassin K, Half E.

Rambam Maimonides Med J. 2018 Oct 4;9(4). doi: 10.5041/RMMJ.10353.

4.

Novel prep-less X-ray imaging capsule for colon cancer screening: a feasibility study.

Gluck N, Half EE, Bieber V, Schwartz D, Ron Y, Gralnek I, Klein A, Lachter J, Levy MS, Moshkowitz M, Arber N.

Gut. 2019 May;68(5):774-775. doi: 10.1136/gutjnl-2018-316127. Epub 2018 May 21. No abstract available.

PMID:
29785966
5.

Update on Screening for Urological Malignancies.

Hoffman A, Half EE.

Rambam Maimonides Med J. 2017 Oct 16;8(4). doi: 10.5041/RMMJ.10318. Review.

6.

Loss of CD55 in Eculizumab-Responsive Protein-Losing Enteropathy.

Kurolap A, Eshach-Adiv O, Hershkovitz T, Paperna T, Mory A, Oz-Levi D, Zohar Y, Mandel H, Chezar J, Azoulay D, Peleg S, Half EE, Yahalom V, Finkel L, Weissbrod O, Geiger D, Tabib A, Shaoul R, Magen D, Bonstein L, Mevorach D, Baris HN.

N Engl J Med. 2017 Jul 6;377(1):87-89. doi: 10.1056/NEJMc1707173. Epub 2017 Jun 28. No abstract available.

PMID:
28657861
7.

Features of Patients With Hereditary Mixed Polyposis Syndrome Caused by Duplication of GREM1 and Implications for Screening and Surveillance.

Lieberman S, Walsh T, Schechter M, Adar T, Goldin E, Beeri R, Sharon N, Baris H, Ben Avi L, Half E, Lerer I, Shirts BH, Pritchard CC, Tomlinson I, King MC, Levy-Lahad E, Peretz T, Goldberg Y.

Gastroenterology. 2017 Jun;152(8):1876-1880.e1. doi: 10.1053/j.gastro.2017.02.014. Epub 2017 Feb 24.

PMID:
28242209
8.

The Heparanase Inhibitor PG545 Attenuates Colon Cancer Initiation and Growth, Associating with Increased p21 Expression.

Singh P, Blatt A, Feld S, Zohar Y, Saadi E, Barki-Harrington L, Hammond E, Ilan N, Vlodavsky I, Chowers Y, Half E.

Neoplasia. 2017 Mar;19(3):175-184. doi: 10.1016/j.neo.2016.12.001. Epub 2017 Jan 29.

9.

Guaiac faecal occult blood screening in individuals younger than 50 years of age.

Zalts R, Moadi Z, Avizohar O, Leiba R, Half E, Karban A.

Eur J Cancer Prev. 2017 May;26(3):189-194. doi: 10.1097/CEJ.0000000000000253.

PMID:
27167151
10.

Development and validation of a predictive model for detection of colorectal cancer in primary care by analysis of complete blood counts: a binational retrospective study.

Kinar Y, Kalkstein N, Akiva P, Levin B, Half EE, Goldshtein I, Chodick G, Shalev V.

J Am Med Inform Assoc. 2016 Sep;23(5):879-90. doi: 10.1093/jamia/ocv195. Epub 2016 Feb 15.

11.

Constitutional Mismatch Repair Deficiency in Israel: High Proportion of Founder Mutations in MMR Genes and Consanguinity.

Baris HN, Barnes-Kedar I, Toledano H, Halpern M, Hershkovitz D, Lossos A, Lerer I, Peretz T, Kariv R, Cohen S, Half EE, Magal N, Drasinover V, Wimmer K, Goldberg Y, Bercovich D, Levi Z.

Pediatr Blood Cancer. 2016 Mar;63(3):418-27. doi: 10.1002/pbc.25818. Epub 2015 Nov 6.

PMID:
26544533
12.

An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis.

Lynch PM, Burke CA, Phillips R, Morris JS, Slack R, Wang X, Liu J, Patterson S, Sinicrope FA, Rodriguez-Bigas MA, Half E, Bulow S, Latchford A, Clark S, Ross WA, Malone B, Hasson H, Richmond E, Hawk E.

Gut. 2016 Feb;65(2):286-95. doi: 10.1136/gutjnl-2014-307235. Epub 2015 Mar 19.

13.

The gastrointestinal manifestation of constitutional mismatch repair deficiency syndrome: from a single adenoma to polyposis-like phenotype and early onset cancer.

Levi Z, Kariv R, Barnes-Kedar I, Goldberg Y, Half E, Morgentern S, Eli B, Baris HN, Vilkin A, Belfer RG, Niv Y, Elhasid R, Dvir R, Abu-Freha N, Cohen S.

Clin Genet. 2015 Nov;88(5):474-8. doi: 10.1111/cge.12518. Epub 2014 Nov 10.

PMID:
25307252
14.

Reply: To PMID 23695870.

Half E, Mlynarsky L.

Dig Dis Sci. 2013 Oct;58(10):3057-8. No abstract available.

PMID:
24191347
15.

Gastric microbiota is altered in oesophagitis and Barrett's oesophagus and further modified by proton pump inhibitors.

Amir I, Konikoff FM, Oppenheim M, Gophna U, Half EE.

Environ Microbiol. 2014 Sep;16(9):2905-14. doi: 10.1111/1462-2920.12285. Epub 2013 Oct 22.

PMID:
24112768
16.

False negative fecal occult blood test may be associated with increased mortality from colorectal cancer.

Half EE, Mlynarsky L, Naftali T, Benjaminov F, Konikoff FM.

Dig Dis Sci. 2013 Sep;58(9):2639-45. doi: 10.1007/s10620-013-2702-1. Epub 2013 May 22.

PMID:
23695870
17.

Chemoprevention of gastrointestinal neoplasia.

Half E, Arber N.

Curr Gastroenterol Rep. 2013 May;15(5):320. doi: 10.1007/s11894-013-0320-x. Review.

PMID:
23605648
18.

Effects of age and cholecystectomy on common bile duct diameter as measured by endoscopic ultrasonography.

Benjaminov F, Leichtman G, Naftali T, Half EE, Konikoff FM.

Surg Endosc. 2013 Jan;27(1):303-7. doi: 10.1007/s00464-012-2445-7. Epub 2012 Aug 18.

PMID:
22903627
19.

[Management of hereditary non-polyposis syndrome (Lynch syndrome)].

Kariv R, Goldberg Y, Soler I, Rosner G, Half E, Moshkowitz M, Vilkin A, Levi Z, Niv Y.

Harefuah. 2011 Apr;150(4):392-6, 416. Hebrew.

PMID:
22164924
20.

Treatment of Crohn's disease with cannabis: an observational study.

Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM.

Isr Med Assoc J. 2011 Aug;13(8):455-8. Erratum in: Isr Med Assoc J. 2011 Sep;13(9):582. Yablekovitz, Doron [corrected to Yablecovitch, Doron].

21.

[Guidelines for diagnosis, treatment, surveillance and prevention of cancer in patients with familial non-adenomatous polyposis].

Half E, Goldberg Y, Kariv R, Cohen-Ezra O, Vilkin A, Levi Z, Moshkowitz M, Niv Y; Israeli Gastroenterology Association.

Harefuah. 2011 Jul;150(7):607-10, 615. Hebrew.

PMID:
21874774
22.

[The Israeli recommendations for diagnosis, management, follow-up and prevention of colorectal cancer (CRC) in familial adenomatous polyposis].

Half E, Goldberg Y, Kariv R, Vilkin A, Levi Z, Moshkowitz M, Niv Y; Israeli Gastroenterology Association.

Harefuah. 2011 Jul;150(7):603-6, 616, 615. Hebrew.

PMID:
21874773
23.

Evaluation of difluoromethylornithine for the chemoprevention of Barrett's esophagus and mucosal dysplasia.

Sinicrope FA, Broaddus R, Joshi N, Gerner E, Half E, Kirsch I, Lewin J, Morlan B, Hong WK.

Cancer Prev Res (Phila). 2011 Jun;4(6):829-39. doi: 10.1158/1940-6207.CAPR-10-0243.

24.

The safety and efficacy of celecoxib in children with familial adenomatous polyposis.

Lynch PM, Ayers GD, Hawk E, Richmond E, Eagle C, Woloj M, Church J, Hasson H, Patterson S, Half E, Burke CA.

Am J Gastroenterol. 2010 Jun;105(6):1437-43. doi: 10.1038/ajg.2009.758. Epub 2010 Mar 16.

PMID:
20234350
25.

Familial adenomatous polyposis.

Half E, Bercovich D, Rozen P.

Orphanet J Rare Dis. 2009 Oct 12;4:22. doi: 10.1186/1750-1172-4-22. Review.

26.

Colon cancer: preventive agents and the present status of chemoprevention.

Half E, Arber N.

Expert Opin Pharmacother. 2009 Feb;10(2):211-9. doi: 10.1517/14656560802560153 . Review.

PMID:
19236194
27.

Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells.

Half E, Sun Y, Sinicrope FA.

Cancer Lett. 2007 Jun 28;251(2):237-46. Epub 2006 Dec 26.

PMID:
17189670
28.

Chemoprevention of colorectal cancer: two steps forward, one step back?

Half EE, Arber N.

Future Oncol. 2006 Dec;2(6):697-704. Review.

PMID:
17155896
29.

Mutated DNA in the stool--does it have a role in colorectal cancer screening?

Half EE, Lynch PM.

Nat Clin Pract Gastroenterol Hepatol. 2006 Nov;3(11):594-5. No abstract available.

PMID:
17068491
30.

Clinical management of hereditary colorectal cancer syndromes.

Half EE, Bresalier RS.

Curr Opin Gastroenterol. 2004 Jan;20(1):32-42.

PMID:
15703618
31.
32.

Frequent CpG island methylation in sporadic and syndromic gastric fundic gland polyps.

Abraham SC, Park SJ, Cruz-Correa M, Houlihan PS, Half EE, Lynch PM, Wu TT.

Am J Clin Pathol. 2004 Nov;122(5):740-6.

PMID:
15491970
33.

A circulating ligand for galectin-3 is a haptoglobin-related glycoprotein elevated in individuals with colon cancer.

Bresalier RS, Byrd JC, Tessler D, Lebel J, Koomen J, Hawke D, Half E, Liu KF, Mazurek N; Great Lakes-New England Clinical and Epidemiology Center of the Early Detection Research Network.

Gastroenterology. 2004 Sep;127(3):741-8.

PMID:
15362030
34.

Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.

Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Levin B, Hawk ET, Cohen DS, Ayers GD, Stephens LC; Familial Adenomatous Polyposis Study Group.

Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):920-7.

35.

Treatment of Hereditary Colorectal Cancer Syndromes.

Half EE, Bresalier RS.

Curr Treat Options Gastroenterol. 2004 Jun;7(3):213-224.

PMID:
15149583
36.

HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors.

Half E, Broaddus R, Danenberg KD, Danenberg PV, Ayers GD, Sinicrope FA.

Int J Cancer. 2004 Feb 10;108(4):540-8.

37.
39.

Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.

Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA.

Cancer Res. 2002 Mar 15;62(6):1676-81.

40.

Insulin autoimmune syndrome after therapy with imipenem.

Lidar M, Rachmani R, Half E, Ravid M.

Diabetes Care. 1999 Mar;22(3):524-5. No abstract available.

PMID:
10097941

Supplemental Content

Support Center